Irinotecan liposomal - Champions Oncology
Alternative Names: Irinophore CLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator BC Cancer Agency
- Developer BC Cancer Agency; Champions Oncology
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 06 Apr 2011 Preclinical trials in Cancer in Canada (unspecified route)
- 04 Apr 2011 Champions Biotechnology is now called Champions Oncology